GNS Healthcare Inc. (d/b/a Aitia since 1/23)

https://www.aitiabio.com

LinkedIn: https://www.linkedin.com/company/aitiabio

Aitia is a leader in the application of Causal AI and Digital Twins to discover the next generation of breakthrough drugs. By leveraging the convergence of multi-omic patient data, high-performance computing, and causal learning and AI, Aitia is revealing the hidden biological mechanisms of disease to create Digital Twins of disease in oncology, neurodegenerative disorders, and immunology. Gemini Digital Twins are being used today to discover novel therapies and accelerate R&D in multiple myeloma, prostate cancer, Alzheimer’s Disease, Parkinson’s Disease, and Huntington’s Disease, with several more in development. Aitia’s partners include seven of the top ten pharmaceutical companies, leading academic research and medical centers, medical societies, leading multi-omic data companies, and patient advocacy groups globally. *

	Start	2012-10-01 established
	Group	Aitia (GNS Healthcare) (Group)
	Industry	AI-based drug discovery / AI-based drug development
	Industry 2	digital twin (simulation software / virtual reality (VR))
	Person	Hill, Colin (Aitia 202303 CEO + Co-Founder formerly Gene Network 200708 CEO)
	Person 2	Donahue, Joseph F. (Joe) (GNS Healthcare 202204– CBO before Accenture + GeneDx + Thomson Reuters + Inforsense)

	Region	Somerville, MA
	Country	United States (USA)
	Street	561 Windsor Street
	City	02143 Somerville, MA
	Tel	+1-617-374-2300
		Address record changed: 2024-01-05

Basic data	Employees	n. a.

		* Document for »About Section«: UCB S.A.. (3/15/23). "Press Release: Aitia and UCB Announce Strategic Drug Discovery Collaboration in Huntington's Disease". Brussels & Somerville, MA.

		Record changed: 2023-07-10